• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Podcast: This Week in Managed Care—Bringing Down Health Insurance Premiums and Other Health News

Podcast

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care stories include Senator Bill Cassidy's new plan to lower healthcare costs; policy recommendations from the American Diabetes Association on how to lower insulin prices; and coverage from the American Society of Clinical Oncology annual meeting.

To listen, login to the website.

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Listen above or through one of these podcast services:

Senator Cassidy Unveils Proposal to Lower Healthcare Costs

ADA Issues Recommendations Designed to Fix Insulin Pricing, Accessibility Crisis

Persephone Trial: Cutting Trastuzumab Duration by Half Safer, Efficacious in HER2-Positive Breast Cancer

Remote Monitoring Can Reduce Radiation-Related Symptoms in Head and Neck Cancer

2018 American Society of Clinical Oncology Annual Meeting

Pembrolizumab Improved OS, PFS as First-Line Treatment in NSCLC

What We're Reading: WellCare—Meridian Deal; Virginia Set to Expand Medicaid; High Court Rebuffs Planned Parenthood

Seema S. Sonnad Emerging Leader in Managed Care Research Award

Read more about the stories in this podcast:

Related Videos
Dr Elise Tremblay
Marry Vuong, PharmD, BCPPS
Dr Elise Tremblay
Marry Vuong, PharmD, BCPPS
Marry Vuong, PharmD, BCPPS
Dr Sundar Jagannath
CK Wang, MD, COTA
Eric Lander, MD
Related Content
Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

August 6th 2025
Article

Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.

Read More

managed care cast logo

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

July 24th 2025
Podcast

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

Listen

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

August 4th 2025
Article

Digital patient profiles and expansive real-world data are reshaping oncology clinical trials, explained Gen Li, PhD, MBA, president and founder of Phesi.

Read More

Managed Care Cast

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

July 15th 2025
Podcast

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

Listen

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

July 31st 2025
Article

A significant number of patients with cancer, caregivers, and health care professionals face significant disparities in legal issues, with the most common needs revolving around health insurance, finances, employment, and disability insurance.

Read More

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

July 30th 2025
Article

A retrospective analysis found whole brain radiation therapy alongside immune checkpoint inhibitors led to “brilliant” 2-year overall survival rates.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.